NST-001

Phase 1Small molecule

NNeuroSystec Corporation

NST-001 is one of 35 small molecule programs targeting Tinnitus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TinnitusActive, not recruiting

TinnitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Tinnitus

#DrugCompanyPhaseTrials

Levitra

Bayer

Approved

—2

Decadron

AAspen Global Incorporated

Approved

1 3

Paxil

SSebela Pharmaceuticals Development LLC

Xylocaine

Pitocin

1 6

Zulresso

Biogen

Phase 2

1 7

Neurontin

VViatris Specialty LLC

Phase 2

3 8

Deanxit

RRenJi Hospital

Approved

1 9

Enbrel

IImmunex

Phase 2

1 10

Galzin

AAmerican Regent, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tinnitus1 trial

Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus

Terminated·NNeuroSystec Corporation·Phase 1·NCT00957788·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NST-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NST-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NST-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroSystec Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNeuroSystec Corporation

NST-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tinnitus1 trial

References

Drug Info

Quick Facts

Related News